Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.

"Conflict-of-interest disclosure: U.A.S. reports grants from MSK Paul Calabresi Career Development Award for Clinical Oncology K12CA184746, Paula and Rodger Riney Foundation, Parker Institute for Cancer Immunotherapy at MSK, HealthTree Foundation, International Myeloma Society, American Society of Hematology Scholar Award, and Allen Foundation Inc, as well as nonfinancial support from American Society of Hematology Clinical Research Training Institute and Transdisciplinary Research in Energetics and Cancer Research Training Workshop R25CA203650 (principal investigator: Melinda Irwin); other research support from Celgene/Bristol Myers Squibb (BMS) and Janssen to their institution; and personal fees from Association of Community Cancer Centers, MashUp MD, Janssen Biotech, Sanofi, BMS, MJH Life Sciences, Intellisphere, Phillips Gilmore Oncology Communications, RedMedEd, and i3Health. E.J.G. reports consulting for Novartis, Flare Therapeutics, and Seagen. S.P. reports research support from Amgen Inc, Celgene/BMS Corporation, Multiple Myeloma Research Foundation, GRAIL, and Caribou, and serves on the advisory board for GRAIL and Genentech. S.J. is a consultant for Janssen, BMS, Legend Biotech, Regeneron, Caribou, Sanofi, Takeda, and Karyopharm; is DMC chairman for Genmab and Sanofi; and has membership on an entity’s board of directors or advisory committees for International Myeloma Society, American Society of Hematology, and Society of Hematologic Oncology. C.R.T. reports research funding from Janssen and Takeda; personal fees from MJH Life Sciences; and has participated in advisory boards for Janssen and Sanofi, outside of the submitted work. M.H. reports research funding from Amgen, Daiichi Sankyo, and GlaxoSmithKline, and has received honoraria for consultancy/participated in advisory boards for Curio Science LLC, Intellisphere LLC, BMS, and GlaxoSmithKline. H.H. reports grants from Celgene, Takeda, and Janssen, outside the submitted work. S.M. reports consulting fees from Evicore, Optum, BioAscend, Janssen Oncology, and Legend Biotech. S.M. receives research funding from the National Cancer Institute, Janssen Oncology, BMS, Allogene Therapeutics, Fate Therapeutics, and Takeda Oncology, to the institution for research outside the submitted work, and has received honoraria from OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications, outside the submitted work. K.M. reports grant support from American Society of Hematology, Multiple Myeloma Research Foundation, and International Myeloma Society. A.L. reports grants from Novartis and BMS; personal fees from Trillium Therapeutics; grants, personal fees, and nonfinancial support from Pfizer; grants and personal fees from Janssen, outside the submitted work; holds a patent US20150037346A1 with royalties paid; and serves on the data safety monitoring board for ArcellX. S.Z.U. received research funding from Amgen, Array Biopharma, BMS, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; is a consultant to AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, and TeneoBio; and is also a speaker with Amgen, BMS, Janssen, and Sanofi. N.K. reports research funding through Amgen, Janssen, Epizyme, AbbVie; consults for Clinical Care Options, OncLive, and Intellisphere Remedy Health; and participated in advisory board for Janssen. A.C. reports research support from Amgen, Array Biopharma, Celgene, GlaxoSmithKline, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Oncoceutics, Pharmacyclics, and Seattle Genetics; reports consultancy fees from Amgen, BMS, Celgene, Millennium/Takeda, Janssen, and Karyopharm; and declares membership on the scientific advisory board for Amgen, Celgene, Millennium/Takeda, Janssen, Karyopharm, Sanofi, and Seattle Genetics. H.J.C. is employed by the Multiple Myeloma Research Foundation and has research support from BMS, Takeda, and Genentech, outside the submitted work. J.R. is a consultant/adviser for Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, and AbbVie, and is a member of the speaker’s bureau for Janssen, BMS, Sanofi, and Adaptive Biotechnologies. A.R. is a consultant for Sanofi, BMS, Janssen, and Adaptive. C.R. is a consultant for Janssen, BMS, Takeda, Sanofi, and Artiva. The remaining authors declare no competing financial interests."

"This study is funded, in part, through the National Institutes of Health (10.13039/100000002NIH)/National Cancer Institute (10.13039/100000054NCI) Cancer Center support grants, 10.13039/100007052Memorial Sloan Kettering grant P30 CA008748, and Tisch Cancer Institute grant P30 CA196521. U.A.S. received research support from the 10.13039/100000054NCI Memorial Sloan Kettering Cancer Center (10.13039/100007052MSK) Paul Calabresi Career Development Award for Clinical Oncology K12 CA184746, the American Society of Hematology Scholar Award, the Parker Institute for Cancer Immunotherapy at MSK Career Development Award, and the International Myeloma Society Career Development Award. She also received research funding from the Paula and Rodger Riney Foundation, HealthTree Foundation, the Allen Foundation Inc, the Willow Foundation, the David Drelich, Irrevocable Trust Transdisciplinary Research in Energetics and Cancer Research Training Workshop R25CA203650 (principal investigator: Melinda Irwin), and the American Society of Hematology Clinical Research Training Institute. E.J.G. reports research support and salary support from NIH/NCI R37CA266853. S.P. reports grant support from NIH/NCI R01CA252222, NIH/NCI R01CA244899, and NIH/NCI UH2 CA271390."